KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBITDA Margin: 2017-2025

Historic EBITDA Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to 8.97%.

  • Amneal Pharmaceuticals' EBITDA Margin fell 368.00% to 8.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.19%, marking a year-over-year increase of 519.00%. This contributed to the annual value of 8.92% for FY2024, which is 39.00% up from last year.
  • Amneal Pharmaceuticals' EBITDA Margin amounted to 8.97% in Q3 2025, which was down 41.67% from 15.37% recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' EBITDA Margin registered a high of 15.37% during Q2 2025, and its lowest value of -35.51% during Q2 2022.
  • Moreover, its 3-year median value for EBITDA Margin was 12.20% (2023), whereas its average is 9.80%.
  • Per our database at Business Quant, Amneal Pharmaceuticals' EBITDA Margin tumbled by 4,805bps in 2022 and then soared by 4,888bps in 2023.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' EBITDA Margin stood at 2.08% in 2021, then spiked by 383bps to 5.91% in 2022, then crashed by 361bps to 2.30% in 2023, then skyrocketed by 807bps to 10.38% in 2024, then crashed by 368bps to 8.97% in 2025.
  • Its EBITDA Margin stands at 8.97% for Q3 2025, versus 15.37% for Q2 2025 and 14.43% for Q1 2025.